Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Tenax Therapeutics (NASDAQ:TENX) and maintained a $6 price target for the company's stock.

November 13, 2023 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff reaffirmed a Buy rating on Tenax Therapeutics with a $6 price target, indicating a positive outlook for the stock.
Analyst ratings, especially those with a Buy recommendation, can have a positive impact on a stock's short-term performance. The reiteration of the $6 price target suggests a significant upside potential from the current trading price, which could encourage investor interest and buying activity in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100